Abstract
Having a family history of Alzheimer’ s disease (AD) may potentiate cumulative risk associated with phenotypic expression of the ε-4 allele of the apolipoprotein E (APOE) gene. In this study, we compared the genotype distribution and allele frequencies of APOE ε-2 (rs7412) and ε -4 (rs429358) in 537 South African individuals participating in a chronic disease screening program, in order to establish whether AD family history modulates the expression of their dyslipidemic effects. Significant differences in the genotype distribution for APOE ε-2 (p=0.034) as well as APOE ε-4 (p=0.038) were found between study participants with (n=67) and without (n=470) a family history of AD. LDL cholesterol levels were inversely associated with physical activity in the study group with a positive family history of AD (p<0.001) but not in those with a negative family history of AD (p=0.257). Similar to its existing use in the diagnosis of monogenic dyslipidemias such as familial hypercholesterolemia, clinical inquiry regarding family history was identified as an important determinant of eligibility for APOE genotyping performed in the context of chronic disease risk management. To our knowledge, this is the first study to demonstrate the modulating influence of AD family history on expression of a dyslipidemic phenotype associated with the APOE ε-4 allele. Our findings provide the scientific rationale supporting a novel clinical application for APOE genotyping as a means of identifying a genetic subgroup of dyslipidemic patients set to derive the greatest benefit from early lifestyle-based interventions aimed at decreasing cumulative risk for cardiovascular disease and prevention of AD later in life.
Keywords: Alzheimer’ s disease, apolipoprotein E, dyslipidemia, family history, genotype-phenotype association, personalized genomics.
Current Alzheimer Research
Title:Clinical Relevance of Apolipoprotein E Genotyping Based on a Family History of Alzheimer's Disease
Volume: 12 Issue: 3
Author(s): Hilmar K. Luckhoff, Theresa Brand, Dawid P. van Velden, Martin Kidd, Leslie R. Fisher, Susan J. van Rensburg and Maritha J. Kotze
Affiliation:
Keywords: Alzheimer’ s disease, apolipoprotein E, dyslipidemia, family history, genotype-phenotype association, personalized genomics.
Abstract: Having a family history of Alzheimer’ s disease (AD) may potentiate cumulative risk associated with phenotypic expression of the ε-4 allele of the apolipoprotein E (APOE) gene. In this study, we compared the genotype distribution and allele frequencies of APOE ε-2 (rs7412) and ε -4 (rs429358) in 537 South African individuals participating in a chronic disease screening program, in order to establish whether AD family history modulates the expression of their dyslipidemic effects. Significant differences in the genotype distribution for APOE ε-2 (p=0.034) as well as APOE ε-4 (p=0.038) were found between study participants with (n=67) and without (n=470) a family history of AD. LDL cholesterol levels were inversely associated with physical activity in the study group with a positive family history of AD (p<0.001) but not in those with a negative family history of AD (p=0.257). Similar to its existing use in the diagnosis of monogenic dyslipidemias such as familial hypercholesterolemia, clinical inquiry regarding family history was identified as an important determinant of eligibility for APOE genotyping performed in the context of chronic disease risk management. To our knowledge, this is the first study to demonstrate the modulating influence of AD family history on expression of a dyslipidemic phenotype associated with the APOE ε-4 allele. Our findings provide the scientific rationale supporting a novel clinical application for APOE genotyping as a means of identifying a genetic subgroup of dyslipidemic patients set to derive the greatest benefit from early lifestyle-based interventions aimed at decreasing cumulative risk for cardiovascular disease and prevention of AD later in life.
Export Options
About this article
Cite this article as:
K. Luckhoff Hilmar, Brand Theresa, P. van Velden Dawid, Kidd Martin, R. Fisher Leslie, J. van Rensburg Susan and J. Kotze Maritha, Clinical Relevance of Apolipoprotein E Genotyping Based on a Family History of Alzheimer's Disease, Current Alzheimer Research 2015; 12 (3) . https://dx.doi.org/10.2174/1567205012666150302154354
DOI https://dx.doi.org/10.2174/1567205012666150302154354 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of the Brain Renin-Angiotensin System in Neurodegenerative Disorders
Current Alzheimer Research Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Pharmaceutical Design MTDL Design Strategy in the Context of Alzheimers Disease: From Lipocrine to Memoquin and Beyond
Current Pharmaceutical Design Tau as a Molecular Marker of Development, Aging and Neurodegenerative Disorders
Current Aging Science Hypothyroidism and Endothelial Function: A Marker of Early Atherosclerosis?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Alzheimer's disease: Targeting the Cholinergic System
Current Neuropharmacology Oxidative/Nitrosative Brain Damage in Stress: Possible Target for Neuropsychopharmacological Drugs
Current Medicinal Chemistry - Central Nervous System Agents Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design The Pharmacological Management of Delirium in Critical Illness
Current Drug Therapy Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Effects of ε4 on Object Recognition in the Non-Demented Elderly
Current Aging Science Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews Diagnosis in PANDAS: An Update
Current Psychiatry Research and Reviews Alzheimer’s Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory ‘Wounding’ to Anti-inflammatory ‘Healing’
Current Alzheimer Research Treatment Approaches in Elderly Patients with Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry Is Plasma Amyloid-β a Reliable Biomarker for Alzheimers Disease?
Recent Patents on CNS Drug Discovery (Discontinued) Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets Homocysteine Enhances Transmigration of Rat Monocytes through a Brain Capillary Endothelial Cell Monolayer via ICAM-1
Current Neurovascular Research Commentary: Research Highlights: IKKβ Mediates Aβ-Triggered Microglial Inflammation and Neuronal Death During Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets